Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (delta 2(E)-valproate) in healthy male volunteers.

Literature DB >> 1502017

Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (delta 2(E)-valproate) in healthy male volunteers.

Abstract

2-n-Propyl-2(E)-pentenoic acid (delta 2(E)-valproate) was administered to healthy volunteers in oral doses of 50-800 mg. The drug was tolerated well and no significant adverse effects were observed. Pharmacokinetic parameters were determined. Valproate and 3-keto-valproate were detected as metabolites.

Entities: Chemical

Mesh：

Substances：

Year: 1992 PMID： 1502017 DOI： 10.1007/bf01962708

Source DB: PubMed Journal: Pharm Weekbl Sci ISSN： 0167-6555

15 in total

Review 1. Valproate: an updated review.

Authors: L Gram; K D Bentsen
Journal: Acta Neurol Scand Date: 1985-08 Impact factor: 3.209

2. A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations.

Authors: H Nau; R Zierer; H Spielmann; D Neubert; C Gansau
Journal: Life Sci Date: 1981-12-28 Impact factor: 5.037

3. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy.

Authors: W Löscher; H Nau; C Marescaux; M Vergnes
Journal: Eur J Pharmacol Date: 1984-03-23 Impact factor: 4.432

4. The fetal valproate syndrome.

Authors: J H DiLiberti; P A Farndon; N R Dennis; C J Curry
Journal: Am J Med Genet Date: 1984-11

5. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures.

Authors: B J Wilder; R E Ramsay; J V Murphy; B J Karas; K Marquardt; E J Hammond
Journal: Neurology Date: 1983-11 Impact factor: 9.910

6. Fatal liver failure in 16 children with valproate therapy.

Authors: D Scheffner; S König; I Rauterberg-Ruland; W Kochen; W J Hofmann; S Unkelbach
Journal: Epilepsia Date: 1988 Sep-Oct Impact factor: 5.864

7. Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constant-rate application of the drug and its unsaturated metabolite with an osmotic delivery system.

Authors: H Nau; R Zierer
Journal: Biopharm Drug Dispos Date: 1982 Oct-Dec Impact factor: 1.627

8. Valproic acid hepatic fatalities. II. US experience since 1984.

Authors: F E Dreifuss; D H Langer; K A Moline; J E Maxwell
Journal: Neurology Date: 1989-02 Impact factor: 9.910

9. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice.

Authors: P E Keane; J Simiand; M Morre
Journal: Methods Find Exp Clin Pharmacol Date: 1985-02

Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (delta 2(E)-valproate) in healthy male volunteers.

Review 1. Valproate: an updated review.

2. A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations.

3. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy.

4. The fetal valproate syndrome.

5. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures.

6. Fatal liver failure in 16 children with valproate therapy.

7. Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constant-rate application of the drug and its unsaturated metabolite with an osmotic delivery system.

8. Valproic acid hepatic fatalities. II. US experience since 1984.

9. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice.

Review 10. Verification of the fetal valproate syndrome phenotype.

Review 1. Can we develop improved derivatives of valproic acid?

2. Studies on 2-n-propyl-2(E)-pentenoate (delta 2(E)-valproate) in man.

Review 3. Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile.

Review 4. Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy.